Roche Holding’s Acquisition of Genentech

B. Rajesh Kumar
Additional contact information
B. Rajesh Kumar: Institute of Management Technology

Chapter 34 in Wealth Creation in the World’s Largest Mergers and Acquisitions, 2019, pp 289-293 from Springer

Abstract: Abstract On March 12, 2009, Roche announced a $46.8 billion deal to buy South San Francisco-based Genentech. Genentech over the years were transformed from a startup to an entrepreneurial company which had developed Roche’s best-selling drugs like Avastin, Herceptin, and Rituxan. Roche wanted to absorb the biotech firm’s DNA into its corporate culture. Many of the late-stage clinical trials conducted by Roche involved Genentech products. It was expected that Roche’s main growth could come from expanded uses of Avastin. Unlike Pfizer and Merck, Roche had no interest in generic drugs or consumer products. Roche have become a leader in diagnostics. The acquisition was aimed to improve coordination on product development. With the deal, Roche obtained access to Genentech’s product pipeline beyond the year 2015 and gained access to Genentech’s cash pool of approximately $10 billion. The cumulative return for Roche during the entire acquisition period (initial hostile bid announcement to deal completion) was approximately −9.59%.

Keywords: Genentech; Roche Holding; Cash Pooling; Cumulative Return; Avastin (search for similar items in EconPapers)
Date: 2019
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:mgmchp:978-3-030-02363-8_34

Ordering information: This item can be ordered from
http://www.springer.com/9783030023638

DOI: 10.1007/978-3-030-02363-8_34

Access Statistics for this chapter

More chapters in Management for Professionals from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().